SonoSite, Inc., the Washington-based leader in point-of-care ultrasound technology announced the acquisition of Visualsonics, a privately held company that focuses on real-time ultra high-frequency micro ultrasound technology for the pre-clinical research market for $71 million in cash and debt.

“Visualsonics has developed potentially game changing ultrasound technology that breaks conventional barriers for visualizing superficial soft tissue,” said Kevin M. Goodwin, SonoSite President and CEO in a statement. “Our intention is to integrate Visualsonics’ micro-ultrasound technology with SonoSite’s miniaturization competency and user design to deliver ultra high-frequency micro-ultrasound into clinical medicine. With the ability to image extremely superficial structures at 40 microns, we envision the technology being used in a wide array of clinical markets and applications. These include diagnostic radiology, neonatology, pediatric cardiology, orthopedic medicine, tissue regeneration, and dermatology for cosmetic and clinical disease management. We also see solid potential to continue expanding in pre-clinical markets, such as cardiovascular research, gene therapy, cancer and the overall evaluation of drug therapies.”

Visualsonics is a leading medical technology company specializing in high-frequency micro-ultrasound systems that allows researchers to view soft tissue and superficial resolution. The transaction will diversify SonoSite’s portfolio and strengthen their position in the pre-clinical market, which is valued at $350 million and expected to grow significantly.

The transaction is contingent upon approval of the shareholders of Visualsonics and the customary regulations. The shareholders of SonoSite do not have to approve the acquisition. Upon approval, Visualsonics will be a wholly-owned subsidiary of SonoSite. SonoSite expects the transaction to close in the next month.

Source: SonoSite